Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer
Hulin-Curtis, Sarah L., Petit, Dominique, Figg, W. Douglas, Hsing, Ann W., and Reichardt, Juergen K.V. (2010) Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer. Future oncology, 6 (12). pp. 1897-1913.
PDF (Published Version)
- Published Version
Restricted to Repository staff only
Incidences of prostate cancer in most countries are increasing owing to better detection methods; however, prevention with the use of finasteride, a very effective steroid 5α-reductase type II inhibitor, has been met with mixed success. A wide interindividual variation in response exists and is thought to be due to heritable factors. This article summarizes the literature that attempts to elucidate the molecular mechanisms of finasteride in terms of its metabolism, excretion and interaction with endogenous steroid molecules. We describe previously reported genetic variations of steroid-metabolizing genes and their potential association with finasteride efficacy. Based on the literature, we outline directions of research that may contribute to understanding the interindividual variation in finasteride prevention and to the future development of personalized medicine.
|Item Type:||Article (Refereed Research - C1)|
|Keywords:||androgen, CYP3A4, finasteride, haplotype, personalized medicine, pharmacogenetics, prostate cancer, single, nucleotide polymorphismm, SRD5A2, UGT1A|
|Date Deposited:||03 Mar 2011 03:13|
|FoR Codes:||06 BIOLOGICAL SCIENCES > 0604 Genetics > 060499 Genetics not elsewhere classified @ 50%
11 MEDICAL AND HEALTH SCIENCES > 1112 Oncology and Carcinogenesis > 111203 Cancer Genetics @ 50%
|SEO Codes:||92 HEALTH > 9299 Other Health > 929999 Health not elsewhere classified @ 100%|
|Citation Count from Web of Science||